with other network nodes. In contrast, central network nodes normally have many edges and are often transcription factors (TFs) or other regulatory genes that have not been usually associated with disease. 2 Because master regulators of networks are hotspots for gene regulation and have been experimentally proven to predict molecular outcomes of network activity, 3 they have also been found to be key drivers in disease. Thus, they are potential drug targets. In fact, several drug candidates targeting master regulators in disease networks of obesity and type II diabetes mellitus 3 are now in phase III clinical trials (E. Schadt and Merck Inc, personal communication).
Recently, we used a data-driven genome-wide approach to identify a gene module central to human atherosclerosis (A-module). Cluster analysis of 278 mRNA profiles from 5 CAD-relevant tissues-atherosclerotic arterial wall, nonatherosclerotic arterial wall, liver, skeletal muscle, and visceral fat-isolated in the Stockholm Atherosclerosis Gene Expression (STAGE) study 4 revealed 60 tissue-specific clusters. In 2 overlapping clusters, 1 each in atherosclerotic arterial wall and visceral fat, gene activity was independently associated with the extent of coronary atherosclerosis. Many genes in these clusters were in a third cluster identified from genome-wide mRNA profiles of carotid lesions isolated from patients with carotid stenosis in the STAGE cohort. 4 The 3 clusters contained 128 genes (A-module), and the corresponding expression single-nucleotide polymorphisms (SNPs) were enriched 1.8-fold with inherited risk of CAD. Thirty-eight A-module genes were annotated in The Database for Annotation, Visualization and Integrated Discovery 5, 6 ; of those, 32 (84%) were TEML pathway genes. Within the A-module, the co-TF Lim domain-binding 2 (LDB2) was the only regulatory gene in all 3 tissue clusters.
Preliminary evaluation revealed that LDB2 is expressed in both human and mouse atherosclerotic lesions and by all major lesion cell types. In mice, Ldb2 expression was higher in late lesions (predominantly in macrophage/foam cells) than in early lesions (endothelial cells). Genes encoding LIM domainbinding factors were first isolated in screens of nuclear proteins that bind to LIM domains and bring diverse TFs together to form high-order activation complexes. 7, 8 Proteins containing LIM domains are present in many eukaryotes (but not prokaryotes) and have diverse cellular roles as regulators of gene expression, cytoarchitecture, cell adhesion, cell motility, and signal transduction. 9 Thus, LIM proteins might function as biosensors that mediate communication between the cytosol and nucleus. In humans, 135 LIM-encoding sequences have been located in 58 genes. LIM-binding proteins fulfill their array of biological functions in a complex manner through specific binding of combinations of these targets. LDB2 is highly conserved but scarcely studied.
We hypothesized that LDB2 is an important regulator of TEML/A-module genes possibly involved in atherosclerosis. To test this hypothesis, we analyzed additional monocyte/ macrophage-specific genome-wide RNA data from patients with CAD and non-CAD controls and assessed atherosclerosis development and TEML activity in Ldb2-deficient mice bred onto an atherosclerosis-prone background (Ldb2 -/-Ldlr -/-Apob 100/100 ).
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Materials and Methods
Materials and Methods are available in the online-only Supplement.
Results
A Master Regulator of TEML/A-Module Network Genes in CAD Macrophages
Previously, we used a data-driven whole-genome approach to identify LDB2 as a master regulator (ie, a key TF or co-TF in molecular processes) of A-module genes in the arterial wall. 4 Here, we first determined the extent to which LDB2 is a master regulator of A-module genes (n=128) and all other known TEML genes (n=113). For these studies, we used mRNA profiles isolated from primary monocytes in the blood of STAGE patients (Table 1) . 4 Before RNA isolation, monocytes were differentiated into macrophages in vitro (mimicking macrophage differentiation in TEML). TF regulatory network inference of all 233 genes ( Table I in the online-only Data Supplement) , of which 18 encoded TFs or co-TFs, was performed at Z score of 40% (P=0.012). Of the 233 genes, 164 (76 TEML, 82 A-module, and 6 in common) were part of a highly interconnected TF regulatory network in CAD blood macrophages ( Figure 1A ; Figure  I and Table I in the online-only Data Supplement). The most connected genes were LDB2 (31 connections) and RHOH and NR1H3 (23 connections each; Figure 1B ). Next, we examined the role of LDB2 in TEML/A-module networks inferred from 5 sets of mRNA profiles isolated from primary blood monocytes/macrophages in non-CAD controls (3 GSE982 data sets, GSE6054, GSE8921). In TEML/A-module networks inferred from 2 of the GSE9820 data sets of differentiated macrophages ( Figure 1C ; Table II in the online-only Data Supplement) and lipopolysaccharide-stimulated monocytes, LDB2 had 18 connections, making it the third most connected TF (of 18). In 3 data sets (GSE6054, GSE8921, and 1 GSE9820) of mRNA profiles from nonstimulated primary monocytes, LDB2 had 10 connections in 2 networks and 5 connections in 1, representing the 13th or 14th most connected TF (of 18).
To examine disease causalities of the TF regulatory network genes from CAD macrophages, we determined their enrichment in CAD/myocardial infarction (MI) risk (see Materials and Methods), using the genome-wide association CAD database from the Wellcome Trust Case-Control Consortium (WTCCC). 10 SNPs in network genes had a 4.5-fold greater enrichment in CAD/MI risk (P=1×10 −156 ) than 5000 randomly selected, equal-sized sets of SNPs, strongly indicating causality for the network genes.
Exacerbated Atherosclerosis in Ldb2 -/-Mice
The role of LDB2 as a TEML master regulator in CAD macrophages suggests that targeting Ldb2 might affect atherosclerosis development. To test this hypothesis, we obtained Ldb2 -/mice from Mutant Mouse Regional Resource Center. Ldb2 was targeted by replacing the first exon (of 9) by homologous recombination. We bred the Ldb2 -/mice with Ldlr -/-Apob 100/100 mice and backcrossed to ensure >99% C57/ BL6 strain background. Ldlr -/-Apob 100/100 mice have a humanlike low-density lipoprotein cholesterol profile and are prone to atherosclerosis. 11 Ldb2 deficiency did not affect plasma 
Ldb2 -/-(Ldb2 -/-Ldlr -/-Apob 100/100 ), n=10; Ldb2 +/+ (Ldb2 +/+ Ldlr -/-Apob 100/100 ), n=13. P>0.05 at each age for all Ldb2 -/and Ldb2 +/+ comparisons.
cholesterol, triglyceride, or glucose levels over time or weight at euthanization (Table 2 ). However, after 30 weeks, chowfed Ldb2 -/-Ldlr -/-Apob 100/100 mice had ≈2-fold more aortic atherosclerosis compared with littermate Ldb2 +/+ Ldlr -/-Apob 100/100 controls, as judged by lesion surface areas in pinned-out aortas (Figure 2A , upper panel). A similar difference in atherosclerosis was observed at 25 weeks of age in mice fed a high-fat diet (HFD; 24% of energy; Figure 2A , lower panel). 
Composition of Atherosclerotic Lesions in Ldb2 -/-Mice
Next, we assessed the composition of atherosclerotic lesions in aortic root cross-sections from chow-and HFD-fed Ldb2 -/-Ldlr -/-Apob 100/100 mice and littermate Ldb2 +/+ Ldlr -/-Apob 100/100 controls at 30 and 25 weeks, respectively. Unlike Sudan IV lipid staining of pinned-out aortas, which shows lesion surface area, Oil-Red-O staining of cross-sections of the aortic root shows lesion thickness. Relative to the entire area of each aortic root cross-section, Ldb2 -/-Ldlr -/-Apob 100/100 mice had 50% more Oil-Red-O staining and 67% more staining for the macrophage marker CD68 compared with controls ( Figure 2B and 2C). In contrast, the area of staining for the smooth muscle cell marker SM22α was smaller in Ldb2 -/-Ldlr -/-Apob 100/100 mice ( Figure 2D ); the staining of lesion collagen was largely unaffected ( Figure 2E ). The increase in staining in Ldb2 -/-Ldlr -/-Apob 100/100 mice could reflect a greater number of lesion foam cells (ie, CD68positive cells) or increased lipid accumulation and expression of cell surface CD68 in larger foam cells. To assess these possibilities, we counterstained Oil-Red-O-positive lesion areas (≈200×100 μm) in aortic root cross-sections with hematoxylin and counted nuclei (indicating number of foam cells). In multiple cross-sections of aortic root in 3 Ldb2 -/-Ldlr -/-Apob 100/100 and 3 littermate controls, lesion foam cells were ≈3-fold more abundant in Ldb2 -/mice ( Figure 2F ).
Next, we used the immunohistochemical characteristics of atherosclerotic lesions to determine plaque stability scores, calculated as (SM22α+collagen)/(CD68+Oil-Red-O)% areas 12 of Ldb2 -/-Ldlr -/-Apob 100/100 and littermate Ldb2 +/+ Ldlr -/-Apob 100/100 controls ( Figure 2B-2E ). Ldb2 -/plaques were ≈50% less stable ( Figure 2G ). The compositional differences in the atherosclerotic lesions of Ldb2 -/and wild-type mice in the chow-fed group were also reflected in the aortic root lesions and in the plaque stability scores of 25-week-old HFD-fed mice ( Figure 2B -2E and 2G). Ldb2 -/plaques from HFD-fed mice were ≈42% less stable than those in HFD-fed controls ( Figure 2G ).
Adhesion Molecule Activity in Ldb2 -/-Vascular Wall and Blood Leukocytes
At 30 weeks, the exacerbated atherosclerosis and accumulation of foam cells led to more unstable plaques in Ldb2 -/-Ldlr -/-Apob 100/100 mice than in controls, consistent with increased TEML activity. To determine whether increased TEML activity exacerbated atherosclerosis development, we examined Ldb2 -/-Ldlr -/-Apob 100/100 and littermate controls at 6 to 10 weeks of age, before atherosclerotic lesions formed. In these mice, any differences in molecular phenotypes should be primarily caused by Ldb2 deficiency, whereas in 30-week-old mice, such differences would largely reflect the 2-fold difference in the extent of atherosclerosis. The 2 groups had equally elevated plasma cholesterol levels ( Table 2) and no difference in circulating leukocyte levels ( Figure 3A) .
Genome-wide expression analysis of RNA from the aortic arch of 6 Ldb2 -/-Ldlr -/-Apob 100/100 mice and 6 littermate controls at 6 to 10 weeks of age showed that 40 genes were differentially expressed (false discovery rate <0.05; Table  II in the online-only Data Supplement). The pathways most significantly enriched with these genes-antigen processing and presentation (P=0.0005), viral myocarditis (P=0.001), and cell adhesion (P=0.005)-were all highly enriched with TEML genes. The vascular wall cell adhesion activity at 6 to 10 weeks was supported by an increase in Vcam1 expression ( Figure 3B, left panel) and mirrored by Vcam1 protein expression in aortic root cross-sections ( Figure 3B , upper right panels). Icam1 expression was not significantly increased ( Figure 3C ). In primary leukocytes from 6-to 10-week-old mice, Vcam1 expression was also significantly higher in Ldb2 -/mice than in wild-type controls ( Figure 3D) ; Icam1 expression was not significantly increased ( Figure 3E ). Of note, in 
30-week-old mice, Vcam1 expression was to a large extent colocalized with macrophages within the aortic root lesions in
Ldb2 -/-Ldlr -/-Apob 100/100 mice ( Figure 3B , lower right panels).
TEML Activity in Ldb2 -/-Mice
The early adhesion activity in vascular wall and circulating monocytes in 6-to 10-week-old mice should facilitate TEML. To examine this possibility, we created dorsal air pouches in 6-to 10-week-old Ldb2 -/-Ldlr -/-Apob 100/100 mice and littermate controls by subcutaneous injections of sterile air and 50 ng tumor necrosis factor α. After 24 hours, exudates were extracted and examined by fluorescence-activated cell sorting. 13 Leukocytes in air pouches, especially macrophages and monocytes, were markedly increased in Ldb2 -/-Ldlr -/-Apob 100/100 mice ( Figure 4A ). Next, the migration of leukocytes was examined in the retinal vasculature of 6-to 10-week-old mice by confocal microscopy. In littermate controls, several small leukocytes were observed inside arterioles/ venules ( Figure 4B , upper panels), consistent with reports 14,15 of slightly activated but circulating monocytes in hypercholesterolemic mouse models. These intraluminal small leukocytes were largely absent in equally hypercholesterolemic Ldb2 -/-Ldlr -/-Apob 100/100 mice ( Figure 4B , lower panels). Instead, we saw a few larger leukocytes (eg, macrophages) migrating through the vessel wall ( Figure 4B , lower right panels). Owing to the absence of the intraluminal cells, F4/80 staining was significantly reduced in the retinal vasculature of Ldb2 -/-Ldlr -/-Apob 100/100 mice ( Figure 4C ), despite similar levels of circulating leukocytes ( Figure 3A) . These findings support the notion that TEML activity is increased in Ldb2 -/-Ldlr -/-Apob 100/100 mice, consistent with the results of air-pouch studies ( Figure 4A ).
Effects of Perturbing Physiological LDB2 Expression Levels on Leukocyte Migration In Vitro
To further investigate the role of LDB2 in TEML activity, we examined the migration of primary blood leukocytes from Ldb2 -/-Ldlr -/-Apob 100/100 and littermate controls in vitro after stimulation with monocyte chemotactic protein 1. Consistent with findings in the air-pouch and the retinal vascular models, migration of Ldb2 -/leukocytes was significantly increased ( Figure 4D ). Thus, in the complete absence of Ldb2, the migratory properties of primary leukocytes and TEML activity clearly increased. However, the effects of complete and lifelong absence of a key regulator, such as LDB2, can differ from those of subtle deviations from physiological expression levels. To examine how changes in physiological LDB2 expression levels affect monocyte migration, we measured the migration of human THP1 monocytes in vitro after small interfering RNA inhibition or overexpression of LDB2. Migration was increased by overexpression and decreased by lower expression ( Figure 4D ). Thus, like complete deficiency, LDB2 overexpression increases the migration of human THP1 monocytes, whereas decreased LDB2 expression levels decrease migration.
Arterial Recruitment of Leukocytes in Ldb2 -/-Mice
To determine whether increased TEML activity triggered by LDB2 deficiency is caused by an activated endothelium or activated/migration-prone leukocytes, we performed ex vivo perfusion studies. Latex bead-labeled primary leukocytes from 6-to 10-week-old Ldb2 -/-Ldlr -/-Apob 100/100 mice and littermate controls were perfused in situ into the aortic arches of littermate controls. After 2 hours, adhesion of primary leukocytes from Ldb2 -/-Ldlr -/-Apob 100/100 mice was ≈120% greater than that of control leukocytes, indicating that the leukocyte phenotype is the primary reason for the increased TEML activity ( Figure 4E ). To investigate whether the primary phenotype in leukocytes is unrelated to modification in the circulation (making them more adherent), we investigated the in vitro migration of primary spleen leukocytes, which have not been exposed to the circulation, 16 isolated from the spleen of 6-to 10-week-old Ldb2 -/-Ldlr -/-Apob 100/100 mice and littermate controls. Again, the Ldb2 -/leukocytes had greater migration compared with control leukocytes isolated from littermate controls ( Figure 4D ). Thus, Ldb2 deficiency in leukocytes seems to be the primary cause of their increased migration in Ldb2 -/-Ldlr -/-Apob 100/100 mice.
Leukocyte Proliferation in Ldb2 -/-Mice
Recently, local proliferation within plaques, rather than de novo influx, of macrophages was shown to promote atherosclerosis development. 17 To investigate a possible contribution of macrophage proliferation to the observed increase in atherosclerosis burden in Ldb2-deficient mice, we measured gene and protein expression levels of the proliferation marker Ki67. The proliferation rate as indicated by Ki67 mRNA levels in tumor necrosis factor α-stimulated primary leukocytes isolated from Ldb2-deficient mice was found to be 2-fold higher than in stimulated leukocytes from littermate controls ( Figure 4F, left panel) . The increase in mRNA levels was also found to be mirrored by Ki67 protein expression colocalizing with the CD68 macrophage marker in aortic root cross-sections of 30-weekold Ldb2 -/-Ldlr -/-Apob 100/100 mice ( Figure 4F , right panels). Apparently in parallel to increased TEML activity, Ldb2 deficiency also seems to increase proliferation of lesion macrophages/foam cells that may contribute to exacerbating atherosclerosis.
Functional LDB2 Variant, Risk of CAD/MI, and Extent of Clinical and Subclinical Atherosclerosis
Because LDB2 is a key driver of TEML and atherosclerosis, subtle alterations in its protein levels mediated by functional DNA variants in LDB2 may affect the extent of atherosclerosis and possibly risk for CAD/MI. To test this hypothesis, we identified 5 SNPs distributed in LD-blocks of LDB2 and examined their functionality by reverse transcription polymerase chain reaction analysis of tissues from the STAGE study. 4 For 1 SNP, rs10939673, carriers of the T-allele had lower LDB2 mRNA levels in arterial wall (P=0.004) and mediastinal fat (P=0.001) compared with carriers of the C-allele. To confirm that this SNP had the strongest association with LDB2 expression, we examined associations between all 102 SNPs in LDB2 that were genotyped in the STAGE study 4 (representing all haploblocks) and arterial wall expression of LDB2. rs10939673 had by far the strongest association with LDB2 expression levels ( Figure 5 ).
Consistent with our findings of LDB2 expression levels in human monocytes ( Figure 4D ), examination of the allele distribution of rs10939673 in 2 CAD case/control studies 18, 19 showed that carriers of the minor T-allele were significantly under-represented among CAD cases versus controls in both cohorts ( Table 3 ). In 1926 CAD cases and 2938 population controls in the WTCCC study, 20 rs10939673 was not genotyped, but 1 SNP (rs1496747) genotyped in WTCCC was in LD with rs10939673 (r 2 =0.62). The minor G-allele of rs1496747 was also under-represented among CAD cases (P<0.041).
Next, we examined whether the T-allele also was associated with the extent of atherosclerotic lesions in 2 cohorts in which coronary 18 and carotid 21 lesions had been evaluated by quantitative coronary angiography and B-mode ultrasound, respectively. The rare allele (T) of the functional rs10939673 SNP (associated with lower LDB2 expression) was associated with a lower stenosis score (P=0.040) and a smaller plaque area (P=0.024) in 375 MI cases and with a thinner intimamedia (P=0.004) at the carotid bulb in 3118 healthy subjects ( Table 4 ). The latter association was independent of other established CAD/MI risk factors, including age, sex, smoking, systolic/diastolic blood pressures, body mass index, and plasma levels of triglycerides, high-density lipoprotein, low-density lipoprotein cholesterol, and C-reactive protein (P<0.005).
Discussion
The idea of inhibiting TEML to treat atherosclerosis has not yet been fully examined. 1 Targeting TEML in atherosclerosis is attractive, because leukocyte migration across the endothelium is an early inflammatory event occurring before the differentiation and activation of leukocytes and subsequent downstream cascades of immune and inflammatory reactions. TEML is important in both early and late stages of atherosclerosis, 1 but the TEML pathway is also essential for many, if not all, inflammatory and immune reactions 22 and is particularly crucial as the first defense against pathogens. In fact, impaired TEML induced by targeting nonregulatory pathway genes has caused severe opportunistic infections. 23, 24 Therefore, strategies to target TEML should not disrupt isolated steps in the TEML pathway but should generally downregulate overall TEML activity. From this perspective, our finding that LDB2 is a key network driver of TEML in CAD macrophages and regulates many TEML genes that are causally related to CAD (ie, enriched with inherited CAD risk) is potentially important. Master network regulators are increasingly recognized as key drivers in disease. 25 However, a master regulatory role in a gene network is not proof of a corresponding key driver role in disease, which must be experimentally validated. Our findings in atherosclerosis-prone mice provide such a validation and strongly support the notion that LDB2 is a key driver of TEML, atherosclerosis development, and plaque stability, possibly also promoting proliferation of lesion macrophages. 17 This notion is further supported by our finding of a functional LDB2 variant showing that subtle changes in LDB2 expression levels are relevant to CAD/MI risk and the extent of atherosclerosis. In summary, our study provides strong support for LDB2 as a new candidate target gene for atherosclerosis and CAD.
Apart from our current and previous findings relating to LDB2 expression in the atherosclerotic arterial wall, 4 nothing is known about LDB2 in CAD. Interestingly, however, targeting LDB2 increases fibroblast migration in vitro. 26, 27 Specifically, LDB2 seems to anchor STE20-like kinase, preventing STE20-like kinase-mediated phosphorylation (activation) of the actin-tubulin system, which controls cell migration and motility. It is not known whether regulation of the TEML pathway by LDB2 in monocytes involves STE20-like kinase. In fibroblasts, however, LDB2 seemed to be required in a steady state to maintain normal migration, whereas major deviations (in either direction) leads to increased migration. 26, 27 Thus, it was not surprising that both the complete lack and high overexpression of LDB2 increased leukocyte migration, whereas decreased LDB2 expression inhibited migration ( Figure 4D) . A similar pattern was reported for another key driver in disease, peroxisome proliferator-activated receptor δ, 28 in controlling the inflammatory status of macrophages/ foam cells in atherosclerotic lesions. Briefly, when key drivers regulating many downstream genes are completely depleted (ie, knocked out), the underlying network genes lose their main regulation, resulting in increased activity of the regulated network. But when these key drivers are stimulated or inhibited at more physiological conditions, the effects can be the reverse (ie, inhibition leads to less network activity and stimulation to more), as in our study (Figures 2A and 4D) .
We used the Ldlr -/-Apob 100/100 mouse model to study Ldb2 deficiency. These mice have a plasma lipid profile similar to that of patients with CAD 29,30 with high low-density lipoprotein cholesterol and apolipoprotein B100 levels. Atherosclerosis development in these mice is aggressive and occurs on a chow diet. 11 Because the hypercholesterolemia causes leukocytosis in these mice, 14, 15 they are a convenient model to study TEML during atherogenesis. Because LDB2 is a master regulator of TEML genes in a CAD macrophage regulatory network, we examined TEML activity in a range of in vivo, ex vivo, and in vitro models in these mice. In vivo, we examined how leukocytes migrate into an air-pouch during a longer time period. In this model, Ldb2 deficiency increased migration of leukocytes, macrophages, and monocytes. To visualize migration in vivo, we isolated retinas, which again indicated increased migration of Ldb2 -/leukocytes. Ex vivo perfusion studies helped to establish that the main Ldb2 phenotype is within the leukocytes, not in the arterial wall. An in vitro migration assay confirmed the primary role of Ldb2 in spleen leukocytes. In addition, we found that Vcam1, a key gene for adhesion in the TEML pathway, is upregulated both in Ldb2 -/leukocytes and the aortic arterial wall. Thus, we cannot rule out that LDB2 also is affecting migration in the arterial wall (by increasing monocyte adhesion) besides a direct role in leukocytes. The role of Vcam1 expression in the arterial wall is well established, 31, 32 whereas the significance of the increased expression in LDB2deficient leukocytes and lesion macrophages is unknown.
In conclusion, through its regulatory effects on the TEML pathway, LDB2 is a novel therapeutic target for atherosclerosis and plaque stability. Future studies sorting out the molecular mechanism in leukocytes and the arterial wall by which LDB2 regulates TEML should include STE20-like kinase.
The transendothelial migration of leukocyte (TEML) pathway is important in inflammatory diseases, including atherosclerosis. Several genes in this pathway have been targeted in mice with substantial effects on atherosclerosis development. At least 1 drug (natalizumab) has been developed against the key TEML step of leukocyte adherence. Although natalizumab was effective against targeted diseases (multiple sclerosis and Crohns disease), it can have severe side effects (opportunistic brain infections), highlighting the physiological importance of TEML as the first barrier against viral and bacterial infections. However, this role does not disqualify TEML as a suitable target for inflammatory diseases. Instead, the risk of severe side effects underscores the importance of controlling the overall TEML activity as opposed to hampering key steps in TEML. From this perspective, our finding of a regulatory gene with overall effects on TEML activity is significant. Lim domain binding 2 and possibly its coregulator SLK (STE-20 like kinase) merit further attention as novel targets to lower TEML activity to prevent coronary and carotid artery disease and possibly other inflammatory diseases.
Significance
